GLP-1 Receptor Agonists and Your Blood Tests: What to Expect

Overview.

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — produce meaningful changes across multiple blood test categories. Most changes are beneficial: HbA1c and fasting glucose fall, lipid profiles often improve, and liver enzymes frequently normalise. A few parameters, like eGFR, require careful monitoring at initiation. Understanding which labs change — and why — helps you and your doctor track the medication's effects accurately.

Context: Many people starting GLP-1 therapy are already being monitored for diabetes, metabolic syndrome, or obesity-related conditions. Knowing what your medication is doing to your labs prevents misinterpretation of results: for example, an initial eGFR dip at weeks 1–8 is expected and transient, not a sign of kidney injury. Conversely, persistent liver enzyme elevation on GLP-1 therapy warrants investigation.

Key takeaways.

• HbA1c typically falls 1–2% on semaglutide; tirzepatide can produce reductions of 2–2.3%
• Fasting glucose and fasting insulin both decline, often improving HOMA-IR meaningfully
• Triglycerides tend to fall 15–25%; LDL-C falls modestly (1–7%); HDL may rise slightly
• ALT and GGT commonly improve with weight loss — GLP-1s are used in MASH treatment
• eGFR may dip transiently in the first 8 weeks then stabilises and often improves long-term
• Kidney function monitoring (eGFR, creatinine) is recommended at baseline and periodically

Glycaemic Markers: The Primary Target.

GLP-1 receptor agonists were originally developed as glucose-lowering agents. They work by stimulating insulin release in response to meals, suppressing glucagon, slowing gastric emptying, and reducing appetite. This combination produces reliable reductions in both short-term and long-term glycaemic markers.

HbA1c

Expect a 1.0–1.6% reduction with semaglutide 1 mg (SUSTAIN programme). Tirzepatide produces larger reductions of 2.0–2.3% in the SURPASS-2 trial. Effects depend on baseline HbA1c, dose, and adherence. HbA1c reductions are consistent across eGFR subgroups.

Fasting glucose

Falls proportionally with HbA1c. Post-meal glucose spikes are also reduced due to slowed gastric emptying. Monitor regularly during dose titration to avoid hypoglycaemia if you are also taking insulin or sulphonylureas.

Fasting insulin and HOMA-IR

As insulin resistance improves with weight loss and direct GLP-1 effects, fasting insulin typically falls and HOMA-IR improves. This is one of the most clinically meaningful changes for people with metabolic syndrome.

C-peptide

May decrease as the pancreas requires less insulin secretion once glucose is better controlled. This is expected and does not indicate pancreatic damage in most contexts.

Lipid Panel: Generally Favourable Changes.

GLP-1 receptor agonists produce meaningful improvements in lipid profiles, primarily mediated through weight loss and improved insulin sensitivity. The effects on individual lipid fractions vary but the overall direction is cardioprotective.

Triglycerides

The most consistent lipid benefit — falls 15–25% on average. Reductions are driven by decreased hepatic VLDL production, improved insulin sensitivity, and reduced dietary intake (smaller appetite). People with elevated baseline triglycerides see the largest absolute reductions.

LDL-C and ApoB

Modest reductions in LDL-C (1–7%) are typical, largely mediated by weight loss rather than a direct drug effect on LDL metabolism. ApoB reductions track with LDL-C. If you are also on a statin, your LDL-C may already be optimised — monitor ApoB for residual particle burden.

HDL-C

May increase slightly as metabolic health improves, though changes are modest. An increase in HDL is a positive sign of improving insulin sensitivity.

Non-HDL cholesterol

Typically falls along with triglycerides and LDL-C. This is the preferred monitoring target if ApoB is not being measured.

Liver Enzymes: Often Improve.

GLP-1 receptor agonists reduce hepatic fat accumulation, improve insulin sensitivity, and promote weight loss — all of which address the metabolic drivers of fatty liver disease (MASLD). Clinical evidence supports meaningful improvements in liver enzymes and even histological improvement in MASH (metabolic-associated steatohepatitis).

ALT (alanine aminotransferase)

Often improves substantially — one pilot study found a reduction from 80 to 34 IU/L on semaglutide. A systematic review and meta-analysis found that GLP-1 receptor agonists significantly reduced ALT and GGT in patients with NAFLD/MASLD.

AST (aspartate aminotransferase)

Typically improves in parallel with ALT as hepatic steatosis resolves. If AST rises or fails to improve after 3–6 months, consider hepatological review.

GGT (gamma-glutamyl transferase)

GGT is sensitive to metabolic dysfunction — it often falls meaningfully during the first 3–6 months of GLP-1 therapy as insulin resistance improves.

Rare: drug-induced liver injury

Isolated case reports of semaglutide-associated liver injury exist but are rare. If liver enzymes rise above 3× the upper limit of normal on therapy, discuss with your doctor.

Kidney Function: Monitor at Initiation.

The kidney story for GLP-1 agonists is nuanced. There is an initial haemodynamic effect at the start of therapy that can cause a transient eGFR dip in the first 4–8 weeks. This is distinct from true kidney injury and typically resolves. Long-term, semaglutide has been shown to slow eGFR decline and reduce major kidney outcomes — the FLOW trial (2024) showed a 24% reduction in major kidney events in people with type 2 diabetes and CKD.

eGFR at initiation

Measure baseline eGFR before starting. An initial dip of 1–3 mL/min/1.73 m² in the first 4–8 weeks is expected due to reduced hyperfiltration. This is considered a haemodynamic effect, not kidney damage — it mirrors the initial eGFR dip seen with SGLT2 inhibitors.

eGFR at 6 months

Should stabilise or improve. The FLOW trial found the annual rate of eGFR decline was 0.82 mL/min/1.73 m²/year slower in the semaglutide group compared to placebo. Long-term GLP-1 use appears nephroprotective.

Creatinine and BUN

Monitor in the first 3 months, particularly in patients with pre-existing CKD (eGFR < 60). Dose adjustments may be needed based on renal function for some GLP-1 agents.

Urine albumin-to-creatinine ratio (ACR)

GLP-1 agonists reduce albuminuria in people with diabetic kidney disease. If you have microalbuminuria at baseline, monitor ACR at 6 months — improvement is a positive sign of renal protection.

Other Markers Worth Monitoring.

Several other laboratory values may shift during GLP-1 therapy, either due to the direct drug effect or secondary to weight loss and metabolic improvement.

Uric acid

Often falls with weight loss and improved insulin sensitivity. If you have gout, improving metabolic health on GLP-1 therapy may reduce flare frequency.

hs-CRP (inflammation marker)

Often improves with weight loss and reduced visceral adiposity. A falling hs-CRP confirms broad metabolic improvement.

Haematocrit / haemoglobin

May dip slightly with reduced caloric intake and nutritional changes at initiation. Ensure adequate protein and micronutrient intake to support red cell production. Monitor for iron and B12 status if intake is significantly reduced.

Thyroid (TSH)

GLP-1 agonists have been associated with thyroid C-cell tumours in rodent studies. In humans, the clinical significance is uncertain — routine TSH monitoring is not specifically required by most guidelines, but baseline TSH is reasonable. GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Pancreatic enzymes (amylase, lipase)

Not routinely monitored unless symptoms of pancreatitis develop (severe abdominal pain, nausea, vomiting). Pancreatitis is a rare but recognised risk — stop therapy and seek medical evaluation if symptoms arise.

Recommended Monitoring Schedule.

This is a general framework — your doctor will tailor monitoring to your individual circumstances, baseline conditions, and which GLP-1 agent you are taking.

Before starting

HbA1c, fasting glucose, fasting insulin, full lipid panel, ALT/AST/GGT, eGFR, creatinine, urine ACR (if diabetic), TSH (baseline)

3 months

HbA1c, fasting glucose, eGFR, creatinine, liver enzymes (ALT/AST/GGT)

6 months

Full panel repeat: HbA1c, full lipid panel (including ApoB if available), liver enzymes, eGFR, HOMA-IR (if tracking insulin resistance)

Annually thereafter

Full metabolic review including HbA1c, lipids, liver enzymes, kidney function, uric acid, hs-CRP

FAQs.